非布司他治疗痛风有效果吗？

It is a drug suitable for the long-term treatment of hyperuricemia in patients with gout. Is nafebuxostat effective in treating gout?

The therapeutic effect of febuxostat in the treatment of gout:

To evaluate the efficacy and safety of febuxostat in the treatment of gout patients with hyperuricemia.

Methods: From March 2014 to October 2014, 90 patients with gout and hyperuricemia were randomly divided into allopurinol 300 mg group, febuxostat 40 mg group and 80 mg group in the Rheumatology and Immunology Department of the hospital. 30 patients in each group were observed. Efficacy. In the first month, oral administration of 7.5 mg of meloxicam, once/d, was used to prevent acute attacks; follow-up visits were conducted once a month for a total of 6 months. During this period, liver and kidney function, blood routine, serum uric acid were measured by conventional methods, and joint swelling and pain and gastrointestinal discomfort were assessed.

Results: Follow-up showed that the proportion of serum uric acid ≤0.36mmol/L in the febuxostat 80 mg treatment group was higher than that in the other two groups. This difference was more significant at the 6th month after taking the drug. The febuxostat 80 mg group accounted for 83%, which was higher than the 37% of the febuxostat 40 mg group (P<0.01) and 47% of the allopurinol group (P<0.01).

At each follow-up visit, the febuxostat 80 mg group had the highest decrease in serum uric acid, and was significantly better than the allopurinol group (all P<0.05). In the last two months of follow-up, the decrease in serum uric acid in the febuxostat 40 mg group was lower than that in the 80 mg group (P<0.05). The uric acid-lowering effects of the allopurinol group and the febuxostat 40 mg group were basically similar (P>0.05). There was no significant difference in adverse reactions between the three groups during follow-up.

Conclusion: The ability of 80 mg to lower uric acid is better than that of allopurinol 300 mg and febuxostat 40 mg.

Recommended related hot articles: /newsDetail/74711.html